Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
NEULAND LABS TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
NEULAND LABS Mar-23 |
TEVA PHARMA Dec-13 |
NEULAND LABS/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 2,004 | 3,479 | - | |
Low | Rs | 966 | 3,022 | - | |
Sales per share (Unadj.) | Rs | 928.4 | 1,996.4 | - | |
Earnings per share (Unadj.) | Rs | 127.4 | 124.7 | - | |
Cash flow per share (Unadj.) | Rs | 168.6 | 286.1 | - | |
Dividends per share (Unadj.) | Rs | 10.00 | 109.18 | - | |
Avg Dividend yield | % | 0.7 | 3.4 | 20.0% | |
Book value per share (Unadj.) | Rs | 774.8 | 2,217.6 | - | |
Shares outstanding (eoy) | m | 12.83 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.6 | 1.6 | 98.2% | |
Avg P/E ratio | x | 11.7 | 26.1 | 44.7% | |
P/CF ratio (eoy) | x | 8.8 | 11.4 | 77.5% | |
Price / Book Value ratio | x | 1.9 | 1.5 | 130.8% | |
Dividend payout | % | 7.8 | 87.5 | 9.0% | |
Avg Mkt Cap | Rs m | 19,052 | 2,756,220 | 0.7% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 2,018 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,667.6 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,353.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 11,912 | 1,692,969 | 0.7% | |
Other income | Rs m | 97 | 0 | - | |
Total revenues | Rs m | 12,009 | 1,692,969 | 0.7% | |
Gross profit | Rs m | 2,718 | 463,620 | 0.6% | |
Depreciation | Rs m | 528 | 136,844 | 0.4% | |
Interest | Rs m | 131 | 33,253 | 0.4% | |
Profit before tax | Rs m | 2,157 | 293,523 | 0.7% | |
Minority Interest | Rs m | 0 | 1,333 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,682 | -0.0% | |
Tax | Rs m | 522 | -3,584 | -14.6% | |
Profit after tax | Rs m | 1,635 | 105,758 | 1.5% | |
Gross profit margin | % | 22.8 | 27.4 | 83.3% | |
Effective tax rate | % | 24.2 | -1.2 | -1,982.8% | |
Net profit margin | % | 13.7 | 6.2 | 219.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 7,609 | 1,143,425 | 0.7% | |
Current liabilities | Rs m | 4,390 | 997,163 | 0.4% | |
Net working cap to sales | % | 27.0 | 8.6 | 312.8% | |
Current ratio | x | 1.7 | 1.1 | 151.2% | |
Inventory Days | Days | 6 | 91 | 7.0% | |
Debtors Days | Days | 1,109 | 96 | 1,155.7% | |
Net fixed assets | Rs m | 8,189 | 552,961 | 1.5% | |
Share capital | Rs m | 129 | 4,167 | 3.1% | |
Net worth | Rs m | 9,941 | 1,880,567 | 0.5% | |
Long term debt | Rs m | 742 | 865,653 | 0.1% | |
Total assets | Rs m | 15,798 | 3,868,976 | 0.4% | |
Interest coverage | x | 17.5 | 9.8 | 178.2% | |
Debt to equity ratio | x | 0.1 | 0.5 | 16.2% | |
Sales to assets ratio | x | 0.8 | 0.4 | 172.3% | |
Return on assets | % | 11.2 | 3.6 | 311.1% | |
Return on equity | % | 16.4 | 5.6 | 292.5% | |
Return on capital | % | 21.4 | 4.9 | 434.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,372 | 269,772 | 0.9% | |
From Investments | Rs m | -615 | -95,591 | 0.6% | |
From Financial Activity | Rs m | -1,358 | -323,609 | 0.4% | |
Net Cashflow | Rs m | 403 | -149,429 | -0.3% |
Compare NEULAND LABS With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare NEULAND LABS With: ZIM LABORATORIES SANJIVANI PA VEERHEALTH CARE ALCHEMIST LIMITED ANUH PHARMA
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.